Professor Graham Boulnois, PhD - Partner

Focus: Biotechnology

Summary:
Professor Graham Boulnois joined SVLS as a Venture Partner in 2001 and became a Partner in 2004. Graham is a Director of Delanex, Oxagen, Affinium and Vantia. He has responsibility for overseeing the investment in Cellzome. He was a Director at Lorantis, Alantos (prior to its sale to Amgen) and ESBATech (prior to its sale to Alcon Inc).

Prior Experience:
Before joining SVLS, Graham was Senior Vice Presidentin the R&D function at Aventis Pharma where he had global responsibility forLeadGeneration. Prior to joining Aventis, Graham spent a number of years at Zeneca Pharmaceuticals as Senior Vice President, Discovery Research and then with AstraZeneca Pharmaceuticals as Global Vice President, Enabling Science and Technology. Before joining the pharmaceutical industry, he was Professor of Microbiology, Chairman of Biological Sciences and Pro-Dean of the Science Faculty at Leicester University.

Qualifications:
Graham has a BSc in Biological Science and a PhD in Molecular Biology from the University of Leicester.